Literature DB >> 14648216

Twenty years experience in rapid identification of congenital adrenal hyperplasia in Hungary.

Dóra Török1, Gudrun Eckhardt, János Sólyom.   

Abstract

UNLABELLED: The aim of this study was to assess the effectivity of the identification of patients with congenital adrenal hyperplasia (CAH) in Hungary in the absence of systematic neonatal screening and to estimate the incidence. Dried blood-spot samples of patients clinically suspected at any age to have CAH were collected between 1978 and 1998 throughout the whole country. 17-Hydroxyprogesterone (17-OHP) was measured by radioimmunoassay. Age-specific cut-offs were used. The effectivity of the system was retrospectively assessed. Additional cases were sought to assess the overall incidence of CAH in Hungary. Among the 1,837 patients investigated, 185 cases of CAH were identified. The overall effectivity was 94.7%. The sensitivity and the specificity were 98.9% and 94.2%, respectively. Salt-wasting (SW) boys were, on average, diagnosed 2 weeks later than SW girls, while both boys and girls with the simple virilising (SV) form were diagnosed at similar ages (2 versus 2.5 years). An additional 19 cases were diagnosed during the study period using other methods (plasma and urinary steroid profiles without blood-spot 17-OHP measurements). The incidence of classical CAH in Hungary was 1:14,300 (CI 95% between 1:12,450 and 1:16,795). Presuming that the incidence of CAH is the same among boys and girls, one can calculate that the diagnosis was missed in 24 boys (2 SW, 22 SV).
CONCLUSION: it is possible to identify the vast majority of classical cases of congenital adrenal hyperplasia without a neonatal mass screening programme. However, a significant number of boys with the simple virilising form missed whereas both salt-wasting boys and girls are diagnosed safely.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14648216     DOI: 10.1007/s00431-003-1311-y

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  22 in total

Review 1.  Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society.

Authors:  Peter E Clayton; Walter L Miller; Sharon E Oberfield; E Martin Ritzén; Wolfgang G Sippell; Phyllis W Speiser
Journal:  Horm Res       Date:  2002

2.  Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia.

Authors:  S Pang; J Hotchkiss; A L Drash; L S Levine; M I New
Journal:  J Clin Endocrinol Metab       Date:  1977-11       Impact factor: 5.958

3.  Evaluation of neonatal screening for congenital adrenal hyperplasia.

Authors:  J W Honour; T Torresani
Journal:  Horm Res       Date:  2001

4.  Screening for mutations of 21-hydroxylase gene in Hungarian patients with congenital adrenal hyperplasia.

Authors:  A Ferenczi; M Garami; E Kiss; M Pék; M Sasvári-Székely; C Barta; M Staub; J Sólyom; G Fekete
Journal:  J Clin Endocrinol Metab       Date:  1999-07       Impact factor: 5.958

5.  Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia.

Authors:  B L Therrell; S A Berenbaum; V Manter-Kapanke; J Simmank; K Korman; L Prentice; J Gonzalez; S Gunn
Journal:  Pediatrics       Date:  1998-04       Impact factor: 7.124

6.  Value of selective screening for congenital adrenal hyperplasia in Hungary.

Authors:  J Sólyom; I A Hughes
Journal:  Arch Dis Child       Date:  1989-03       Impact factor: 3.791

7.  A comparative cost analysis of newborn screening for classic congenital adrenal hyperplasia in Texas.

Authors:  C A Brosnan; P Brosnan; B L Therrell; C H Slater; J M Swint; J F Annegers; W J Riley
Journal:  Public Health Rep       Date:  1998 Mar-Apr       Impact factor: 2.792

8.  A method for identification and follow-up of patients with a steroid-21-hydroxylase deficiency.

Authors:  J Sólyom; G L Hammond; R Vihko
Journal:  Clin Chim Acta       Date:  1979-03-01       Impact factor: 3.786

9.  Blood-spot 17 alpha-hydroxyprogesterone radioimmunoassay in the follow-up of congenital adrenal hyperplasia.

Authors:  J Sólyom
Journal:  Clin Endocrinol (Oxf)       Date:  1981-06       Impact factor: 3.478

10.  Presentation, acute illness, and learning difficulties in salt wasting 21-hydroxylase deficiency.

Authors:  M D Donaldson; P H Thomas; J G Love; G D Murray; A W McNinch; D C Savage
Journal:  Arch Dis Child       Date:  1994-03       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.